Biostatistics Manager Job Description

Biostatistics Managers are responsible for the quality, timeliness, and regulatory rigor of statistical work across multiple clinical programs. They lead the people who produce the statistical analyses that support FDA submissions and clinical decisions, and they're accountable when those analyses are late, wrong, or fail regulatory review.

The management dimension is genuine and demanding. A team of 6–10 biostatisticians is covering programs at different stages — early-phase first-in-human studies, complex Phase II adaptive trials, and late-phase pivotal programs in their final submission sprint. Each statistician is at a different stage of development, has different strengths and development needs, and is working under different deadline pressures. The manager's job is to keep all of those plates spinning: making sure senior statisticians are getting complex programs, that junior statisticians have adequate supervision, that the team has workload capacity to absorb a new program that just got funded, and that the person who just returned from parental leave has a sensible re-entry plan.

FDA interactions are a defining aspect of senior biostatistics management. Pre-NDA meetings require the manager to help prepare statistical analyses that anticipate FDA reviewers' questions and to participate (often as the statistical lead or support lead) in the actual meeting with FDA. FDA statistical reviewers are sophisticated, ask hard questions, and sometimes disagree with analysis choices in ways that require substantive statistical arguments to resolve. The manager builds the team's FDA experience and develops the institutional knowledge of how specific reviewers in specific FDA divisions think.

CRO management is also substantial. Most pharmaceutical companies outsource some or all clinical trial statistical work, which means managing external statistical teams, setting quality expectations, reviewing deliverables, and addressing problems when CRO statisticians produce work that doesn't meet internal standards or regulatory expectations.

Education:

• Ph.D. in biostatistics or statistics: standard at major pharmaceutical companies for manager roles
• M.S. plus extensive experience occasionally accepted at smaller companies and CROs
• Strong quantitative foundation is non-negotiable; the management role requires maintaining technical credibility with the team

Technical experience (must have before moving to management):

• Multiple Phase II/III programs completed from SAP through CSR
• NDA or BLA submission experience — having seen a regulatory submission through FDA review
• SAP authorship and review for complex designs: adaptive, survival, longitudinal, missing data
• SAS and/or R proficiency; ability to review programming outputs and catch errors
• Deep knowledge of ICH guidelines: E6(R2) GCP, E8(R1), E9(R1) estimands, E17 multi-regional

Leadership and management skills:

• Experience mentoring junior biostatisticians — conducting technical reviews, providing growth-oriented feedback
• Cross-functional collaboration on program teams; demonstrated ability to communicate statistical issues to non-statisticians
• CRO oversight experience — managing external statistical vendors, reviewing SOWs, escalating quality issues
• Performance management: conducting reviews, setting development goals, navigating performance improvement

What differentiates strong management candidates:

• The ability to articulate their statistical methodology decisions clearly to FDA reviewers or senior leadership
• A track record of developing junior team members who advanced — this demonstrates management capability better than claiming it
• Experience with at least one full regulatory submission cycle, not just contributing to sections of one

Biostatistics leadership roles are among the most secure and well-compensated scientific management positions in the pharmaceutical industry. The regulatory mandate for statistical rigor in clinical programs means that a capable, experienced biostatistics manager is essential infrastructure for any company running pivotal clinical trials — and replacing one is neither fast nor cheap.

The supply of qualified biostatistics managers is genuinely limited. A strong candidate needs a Ph.D. in biostatistics, 8–12 years of clinical development experience, NDA or BLA submission experience, and demonstrated team leadership skills. This combination takes a long time to develop, and the academic pipeline producing Ph.D. biostatisticians doesn't expand quickly enough to eliminate the long-standing supply shortfall.

The Biostatistics function has grown in organizational influence as the complexity of clinical trial methodology has increased. FDA's adoption of the ICH E9(R1) estimands framework required companies to fundamentally reconsider how they specify primary analyses, handling of intercurrent events, and sensitivity analysis strategies. Navigating this transition well has elevated the visibility of biostatistics leaders within clinical development leadership.

Adaptive clinical trial designs — response-adaptive randomization, seamless Phase II/III designs, master protocols — are being used in a broader range of therapeutic areas. Each of these requires substantial statistical expertise to implement and defend to regulatory agencies. Biostatistics managers who have led adaptive programs and worked with FDA on their approval are rare enough that they can largely name their next opportunity.

Real-world evidence has created a parallel demand track for biostatisticians with observational data expertise. Health economics and outcomes research (HEOR) divisions, payer evidence teams, and late-phase RWE groups are all part of larger biostatistics organizations at major pharmaceutical companies, broadening the management scope and organizational influence of biostatistics leadership.

Dear Hiring Manager,

I'm writing to apply for the Biostatistics Manager position at [Company]. I've been with [Current Company] for seven years, the last two as a Senior Biostatistician leading the statistical strategy for a Phase III oncology program that completed last year and whose NDA submission is currently under FDA review.

In that senior role I've functioned as the de facto statistical lead for a team of three other statisticians on that program — reviewing their SAPs, managing the SAP-to-TLF-to-CSR production sequence during the 14-month submission preparation period, and preparing the statistical materials for two pre-NDA meetings with FDA's Oncology division. The technical review has been straightforward, but I'll be direct about what I learned: the experience of sitting across from FDA reviewers defending methodological decisions made two years earlier under very different project circumstances is the most valuable thing I could have done before moving into formal management.

I've also been the department's point person for CRO statistical oversight on two smaller Phase II programs. That work has been humbling in specific ways — understanding why CRO statisticians make the choices they do when the specification isn't tight enough is a different challenge than doing the work yourself.

I'm ready to take on formal management scope. I've been mentoring two junior statisticians for 18 months, conducting structured statistical reviews of their SAPs and sitting with them on FDA interaction calls. The feedback I've received from them has been positive, and watching them grow their FDA-facing communication skills has been the most satisfying part of my current role.

I'd welcome a conversation about your team's structure and what you're looking to build.

[Your Name]